{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:30:41Z","timestamp":1795159841844,"version":"4.10.3"},"reference-count":16,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Foxp3+ regulatory T cells (Tregs) play a central role in maintaining immune tolerance. A reduction in the function of Tregs is a key feature of autoimmune diseases, whereas their expansion in malignant diseases leads to the suppression of host antitumor responses. We analyzed the absolute number of CD4+ and CD8+ Tregs in the peripheral blood of 52 patients with myelodysplastic syndrome (MDS) and show a significant correlation between increased number of CD4+ Tregs and MDS subgroups with 5% or more bone marrow blasts (P &amp;lt; .001), high International Prognostic Scoring System (IPSS) score (P &amp;lt; .001), and disease progression (P &amp;lt; .001), whereas no correlation between CD8+ Tregs and prognostic variables was observed. The CD4+ Tregs showed a polyclonal spectratype, and the percentage of the naive subset was significantly higher in the high-risk patients compared with low-risk or healthy age-matched donors (P = .032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease.<\/jats:p>","DOI":"10.1182\/blood-2007-01-067546","type":"journal-article","created":{"date-parts":[[2007,4,6]],"date-time":"2007-04-06T01:01:08Z","timestamp":1175821268000},"page":"847-850","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":240,"title":["CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)"],"prefix":"10.1182","volume":"110","author":[{"given":"Shahram Y.","family":"Kordasti","sequence":"first","affiliation":[{"name":"Department of Hematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ingram","sequence":"additional","affiliation":[{"name":"Department of Hematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Hayden","sequence":"additional","affiliation":[{"name":"Department of Hematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Darling","sequence":"additional","affiliation":[{"name":"Department of Hematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Barber","sequence":"additional","affiliation":[{"name":"Department of Hematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behdad","family":"Afzali","sequence":"additional","affiliation":[{"name":"Immunoregulation Laboratory, Department of Nephrology and Transplantation, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Immunoregulation Laboratory, Department of Nephrology and Transplantation, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin W.","family":"Wlodarski","sequence":"additional","affiliation":[{"name":"Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Foundation, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Farzaneh","sequence":"additional","affiliation":[{"name":"Department of Hematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[{"name":"Department of Hematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020071613282940000_B1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0145-2126(01)00083-2","article-title":"Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process.","volume":"25","author":"Epperson","year":"2001","journal-title":"Leuk Res"},{"key":"2020071613282940000_B2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood-2004-10-4045","article-title":"Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia.","volume":"106","author":"Wlodarski","year":"2005","journal-title":"Blood"},{"key":"2020071613282940000_B3","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood-2005-09-3902","article-title":"Molecular strategies for detection and quantitation of clonal cytotoxic T cell responses in aplastic anemia and myelodysplastic syndrome.","volume":"108","author":"Wlodarski","year":"2006","journal-title":"Blood"},{"key":"2020071613282940000_B4","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2002-01-0155","article-title":"Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.","volume":"100","author":"Kochenderfer","year":"2002","journal-title":"Blood"},{"key":"2020071613282940000_B5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","article-title":"A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.","volume":"18","author":"Stadler","year":"2004","journal-title":"Leukemia"},{"key":"2020071613282940000_B6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","article-title":"A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u201clow-risk\u201d myelodysplasia.","volume":"120","author":"Killick","year":"2003","journal-title":"Br J Haematol"},{"key":"2020071613282940000_B7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1600-0609.2005.00537.x","article-title":"Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.","volume":"75","author":"Wang","year":"2005","journal-title":"Eur J Haematol"},{"key":"2020071613282940000_B8","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"2020071613282940000_B9","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"2020071613282940000_B10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nm0402-379","article-title":"Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.","volume":"8","author":"Appay","year":"2002","journal-title":"Nat Med"},{"key":"2020071613282940000_B11","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","article-title":"Phenotypic and functional separation of memory and effector human CD8+ T cells.","volume":"186","author":"Hamann","year":"1997","journal-title":"J Exp Med"},{"key":"2020071613282940000_B12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/eji.1830220522","article-title":"An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29\/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction.","volume":"22","author":"Genevee","year":"1992","journal-title":"Eur J Immunol"},{"key":"2020071613282940000_B13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2004-05-2017","article-title":"Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.","volume":"106","author":"Sloand","year":"2005","journal-title":"Blood"},{"key":"2020071613282940000_B14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00277-005-0030-z","article-title":"Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis.","volume":"8","author":"Muller-Berndorff","year":"2006","journal-title":"Ann Hematol"},{"key":"2020071613282940000_B15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0145-2126(02)00096-6","article-title":"A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q\u2212 syndrome from refractory anemia in primary myelodysplastic syndrome.","volume":"27","author":"Cermak","year":"2003","journal-title":"Leuk Res"},{"key":"2020071613282940000_B16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1521-6926(04)00073-8","article-title":"Pathobiology, classification, and diagnosis of myelodysplastic syndrome.","volume":"17","author":"Mufti","year":"2004","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/3\/847\/1293106\/zh801507000847.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/3\/847\/1293106\/zh801507000847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:54:13Z","timestamp":1594943653000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/3\/847\/131993\/CD4CD25high-Foxp3-regulatory-T-cells-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-01-067546","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}